Clinical efficacy and safety of Naftopidil treatment for the patients with benign prostatic hyperplasia: A prospective, open-label, observational study

Yonsei University Health System, Severance Hospital0 个研究点目标入组 120 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

????

•Male ambulatory patients over 50 years of age with LUTS (lower urrinary tract symptom) (total IPSS (International prostate symptom score) greater than 8), who completed the informed consent

•Allergic drug reaction to a1-AR (adrenoreceptor) antagonists, orthostatic hypotension, a history of prostate-related surgery (open or endoscopic), suspicious prostate malignant condition on digital rectal examination and/or prostate-specific antigen (PSA) > 10 ng/ml, a history of recurrent urinary tract infection or bladder stones, renal impairment (creatinine clearance rate <30 ml/min), severe hepatic disorders, the use of anticholinergic or cholinergic agents, the use of other a1-AR (adrenoreceptor) antagonists (tamsulosin, silodosin, alfuzosin, doxazocin, terazocin) within the previous 4 weeks, or the use of 5-reductase inhibitors or antiandrogens within the previous 3 months. Patients who were currently receiving or were planning to take any a-receptor agonists or ß-receptor antagonists were also excluded.

发起方